Poonkiat SuchonwanitSarawin HarnchoowongNongsak ChanasumonTueboon SriphojanartFaculty of Medicine, Ramathibodi Hospital, Mahidol University2020-01-272020-01-272019-01-01Journal of Cosmetic Dermatology. (2019)14732165147321302-s2.0-85069651770https://repository.li.mahidol.ac.th/handle/20.500.14594/52100© 2019 Wiley Periodicals, Inc. Background: Previous studies have proven the efficacy and safety of 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis; however, there is no comparison study between both concentrations. Aims: To compare the efficacy and safety between 0.01% and 0.03% bimatoprost for the treatment of eyebrow hypotrichosis. Patients/Methods: This prospective, randomized, double-blind, split-face clinical study was conducted in 30 patients with eyebrow hypotrichosis. Each side of eyebrow of individual patients was randomly assigned for 0.01% and 0.03% bimatoprost, applied on each eyebrow once daily. Eyebrow density, diameter, the Global Eyebrow Assessment scale, 7-point rating scale, and patient satisfaction were evaluated. Side effects were also recorded. Results: Both 0.01% and 0.03% bimatoprost significantly improved eyebrow density and diameter (P <.05), although there were no statistically significant differences in changes in eyebrow density and diameter from baseline between both concentrations (P =.96 and.84, respectively). Additionally, patients significantly preferred 0.03% bimatoprost in terms of clinical improvement and satisfaction (P =.04 and.003, respectively). Conclusions: Both 0.01% and 0.03% bimatoprost are effective and safe for the treatment of eyebrow hypotrichosis. Bimatoprost 0.03% is superior to its 0.01% counterpart, albeit without statistical significance.Mahidol UniversityMedicineArticleSCOPUS10.1111/jocd.13079